Together, aberrations in PSA levels, AR signaling, and NKX3-1 expression provide growth advantages to prostate cancer cells, while also serving as useful biomarkers of disease status and potential therapeutic targets [19]. This evidence concerns the gene KLK3 and Familial prostate cancer.